Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000049.xml
Download PDF
Clin Colon Rectal Surg 2022; 35(05): 396-401
DOI: 10.1055/s-0042-1746188
DOI: 10.1055/s-0042-1746188
Review Article
Anal Squamous Intraepithelial Lesions and Anal Cancer Management in Low Resource Settings
Abstract
A low resource setting (LRS) is defined as a health care system which does not meet the criteria defined by the World Health Organization (WHO) or other national/international organizations in the following areas: infrastructure, materials, and human resources.1 Patients encounter barriers which limit their access to care and services that are considered standard of care. While LRS is most commonly associated with developing countries, it is easy to overlook communities in developed countries which lack the financial resources to afford basic health care. This article describes the societal implications and barriers to care for both squamous intraepithelial lesions (SILs) and anal cancer in LRS, the existing screening/surveillance approaches, available treatment approaches to anal cancer, and it also discusses potential evidence-based approaches to bridge the gap for these disparities in anal cancer care.
Publication History
Article published online:
13 September 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 van Zyl C, Badenhorst M, Hanekom S, Heine M. Unravelling ‘low-resource settings’: a systematic scoping review with qualitative content analysis. BMJ Glob Health 2021; 6 (06) e005190
- 2 Goldstuck ND. Healthcare in low-resource settings: the individual perspective. Healthc Low Resour Settings 2014;2(02)
- 3 Walker CM, Likes W, Bernard M, Kedia S, Tolley E. Risk of anal cancer in people living with HIV: addressing anal health in the HIV primary care setting. J Assoc Nurses AIDS Care 2016; 27 (05) 563-573
- 4 Sandfort TGL, L Hamilton E, Marais A. et al. The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa (HPTN 075). J Int AIDS Soc 2020; 23 (suppl 6): e25600
- 5 Albuquerque A. High-resolution anoscopy: Unchartered territory for gastroenterologists?. World J Gastrointest Endosc 2015; 7 (13) 1083-1087
- 6 Rosa-Cunha I, Cardenas GA, Dickinson G, Metsch LR. Addressing anal health in the HIV primary care setting: a disappointing reality. AIDS Patient Care STDS 2010; 24 (09) 533-538
- 7 Mendos LR. State-sponsored homophobia. Geneva: Switzerland; 2019
- 8 Baral S, Trapence G, Motimedi F. et al. HIV prevalence, risks for HIV infection, and human rights among men who have sex with men (MSM) in Malawi, Namibia, and Botswana. PLoS One 2009; 4 (03) e4997
- 9 Crowell TA, Keshinro B, Baral SD. et al. Stigma, access to healthcare, and HIV risks among men who sell sex to men in Nigeria. J Int AIDS Soc 2017; 20 (01) 21489
- 10 Albuquerque A, Nathan M, Cappello C, Dinis-Ribeiro M. Anal cancer and precancerous lesions: a call for improvement. Lancet Gastroenterol Hepatol 2021; 6 (04) 327-334
- 11 Farooq O, Farooq A, Ghosh S. et al. The digital divide: a retrospective survey of digital rectal examinations during the workup of rectal cancers. Healthcare. Multidisciplinary Digital Publishing Institute 2021; 9 (07) 855
- 12 Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 (05) 415-422
- 13 Arain S, Walts AE, Thomas P, Bose S. The Anal Pap Smear: cytomorphology of squamous intraepithelial lesions. Cytojournal 2005; 2 (01) 4
- 14 de Ruiter A, Carter P, Katz DR. et al. A comparison between cytology and histology to detect anal intraepithelial neoplasia. Genitourin Med 1994; 70 (01) 22-25
- 15 Friedlander MA, Stier E, Lin O. Anorectal cytology as a screening tool for anal squamous lesions: cytologic, anoscopic, and histologic correlation. Cancer 2004; 102 (01) 19-26
- 16 Velasco J, Palacio V, Vazquez S, Mosquera C, Sampedro A. Diagnostic accuracy of the cytologic diagnosis of anal human papillomavirus infection compared with DNA hybridization studies. Sex Transm Dis 1993; 20 (03) 147-151
- 17 Lacey HB, Wilson GE, Tilston P. et al. A study of anal intraepithelial neoplasia in HIV positive homosexual men. Sex Transm Infect 1999; 75 (03) 172-177
- 18 Panther LA, Wagner K, Proper J. et al. High resolution anoscopy findings for men who have sex with men: inaccuracy of anal cytology as a predictor of histologic high-grade anal intraepithelial neoplasia and the impact of HIV serostatus. Clin Infect Dis 2004; 38 (10) 1490-1492
- 19 Papaconstantinou HT, Lee AJ, Simmang CL. et al. Screening methods for high-grade dysplasia in patients with anal condyloma. J Surg Res 2005; 127 (01) 8-13
- 20 Fox PA, Seet JE, Stebbing J. et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect 2005; 81 (02) 142-146
- 21 Nadal SR, Calore EE, Nadal LR, Horta SH, Manzione CR. Anal cytology for screening of pre-neoplasic lesions. Rev Assoc Med Bras (1992) 2007; 53 (02) 147-151
- 22 Sendagorta E, Herranz P, Guadalajara H. et al. Prevalence of abnormal anal cytology and high-grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men. Dis Colon Rectum 2014; 57 (04) 475-481
- 23 Tramujas da Costa e Silva I, de Lima Ferreira LC, Santos Gimenez F. et al. High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients. Ann Surg Oncol 2008; 15 (05) 1470-1475
- 24 Li YY, Zhang HW, Wang XJ. et al. Value of high-resolution anoscopy in the diagnosis of anal precancerous lesions. Zhonghua Fu Chan Ke Za Zhi 2021; 56 (01) 34-42
- 25 Inkster MD, Wiland HO, Wu JS. Detection of anal dysplasia is enhanced by narrow band imaging and acetic acid. Colorectal Dis 2016; 18 (01) O17-O21
- 26 Fernandez E. Treating anal cancer precursor lesions reduces cancer risk for people with HIV. Groundbreaking National Clinical Trial Halted Due to Therapy's High Success Rates. 2021
- 27 AM Cosortium. Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions (ANCHOR). US National Library of Medicine; 2021
- 28 Weis SE. Current treatment options for management of anal intraepithelial neoplasia. OncoTargets Ther 2013; 6: 651-665
- 29 Megill C, Wilkin T. Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions. Semin Colon Rectal Surg 2017; 28 (02) 86-90
- 30 Richel O, Wieland U, de Vries HJ. et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol 2010; 163 (06) 1301-1307
- 31 Wieland U, Brockmeyer NH, Weissenborn SJ. et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006; 142 (11) 1438-1444
- 32 Fox PA, Nathan M, Francis N. et al. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS 2010; 24 (15) 2331-2335
- 33 Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 2013; 14 (04) 346-353
- 34 NIH SEER Program. “Cancer Stat Facts: Anal Cancer” https://seer.cancer.gov/statfacts/html/anus.html. Accessed 3 November 2021
- 35 Moscicki AB, Darragh TM, Berry-Lawhorn JM. et al. Screening for anal cancer in women. J Low Genit Tract Dis 2015; 19 (3, suppl 1): S27-S42
- 36
Sung H,
Ferlay J,
Siegel RL.
et al.
Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
MissingFormLabel
- 37 Pessia B, Romano L, Giuliani A, Lazzarin G, Carlei F, Schietroma M. Squamous cell anal cancer: management and therapeutic options. Ann Med Surg (Lond) 2020; 55: 36-46
- 38 Kojic EM, Cu-Uvin S, Conley L. et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011; 38 (04) 253-259
- 39 de Martel C, Ferlay J, Franceschi S. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13 (06) 607-615
- 40 Flam M, John M, Pajak TF. et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14 (09) 2527-2539
- 41 UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996; 348 (9034): 1049-1054
- 42 Bartelink H, Roelofsen F, Eschwege F. et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15 (05) 2040-2049
- 43 Colangelo AC, Pizzol D, Antunes M. Anal high-grade and late-stage cancer management in low-income setting: a case report. J Surg Case Rep 2020; 2020 (10) a423
- 44 Zuma NP, Ngidi S, Madiba TE. Anal squamous cell carcinoma in KwaZulu-Natal Province, South Africa, with special reference to the influence of HIV infection on clinical presentation and management outcome. S Afr Med J 2020; 110 (03) 243-248
- 45 Ward ZJ, Scott AM, Hricak H, Atun R. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. Lancet Oncol 2021; 22 (03) 341-350
- 46 Petrosky E, Bocchini Jr JA, Hariri S. et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64 (11) 300-304
- 47 O'leary ST, Maldonado YA, Kimberlin DW. Update from the advisory committee on immunization practices. J Pediatric Infect Dis Soc 2019; 8 (06) 495-500
- 48 Farmer E, Cheng MA, Hung CF, Wu TC. Vaccination strategies for the control and treatment of HPV infection and HPV-associated cancer. Recent Results Cancer Res 2021; 217: 157-195
- 49 Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009; 84 (15) 118-131
- 50 Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012; 54 (07) 891-898
- 51 Deshmukh AA, Chhatwal J, Chiao EY, Nyitray AG, Das P, Cantor SB. Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men. Clin Infect Dis 2015; 61 (10) 1527-1535
- 52 Deshmukh AA, Cantor SB, Fenwick E. et al. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: the time is now. Vaccine 2017; 35 (38) 5102-5109
- 53 Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbidde EK. Universal routine HPV vaccination for young girls in Uganda: a review of opportunities and potential obstacles. Infect Agent Cancer 2012; 7 (01) 24
- 54 Black E, Richmond R. Prevention of cervical cancer in Sub-Saharan Africa: the advantages and challenges of HPV vaccination. Vaccines (Basel) 2018; 6 (03) E61
- 55 DiAngi YT, Panozzo CA, Ramogola-Masire D, Steenhoff AP, Brewer NT. A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PLoS One 2011; 6 (10) e25481
- 56 Penny M, Bartolini R, Mosqueira NR. et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011; 29 (31) 5022-5030
- 57 Biellik R, Levin C, Mugisha E. et al. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009; 27 (44) 6203-6209
- 58 Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012; 90 (08) 623-628